Updated results of a phase II trial of brentuximab vedotin combined with R-CHOP in frontline treatment of patients (pts) with high-intermediate/high-risk diffuse large B-cell lymphoma (DLBCL). Bartlett, N. L., Farber, C. M., Yasenchak, C. A., Ansell, S., Advani, R. H., Knapp, M. H., Fayad, L., Kolibaba, K. S., Patel-Donnelly, D., Seetharam, M., Yimer, H., Manley, T., Burke, J. M., Holkova, B., Budde, L., Halwani, A. AMER SOC CLINICAL ONCOLOGY. 2015

View details for Web of Science ID 000358036901819